vTv Therapeutics, a biotech developing treatments for Alzheimer's disease and type 2 diabetes, raised $117 million by offering 7.8 million shares at $15, the low end of the range of $15 to $17. vTv Therapeutics plans to list on the Nasdaq under the symbol VTVT...read more
The largest biotech ever to go public is on the calendar for this week, targeting a $2.2 billion valuation at IPO. Ten IPOs and two blank check companies plan to raise over $2...read more
vTv Therapeutics, a biotech developing treatments for Alzheimer's disease and type 2 diabetes, announced terms for its IPO on Monday.
The High Point, NC-based company plans to raise $125 million by offering 7.8 million shares at a price range of $15 to $17....read more
US IPO Weekly Recap: "Breaking" news in the IPO market as most deals end down
Breaking news: Two-thirds of this week's IPOs broke issue. Last week, we noted that the recent stretch of strong...read more
vTv Therapeutics prices IPO at $15, the low end of the range
vTv Therapeutics, a biotech developing treatments for Alzheimer's disease and type 2 diabetes, raised $117 million by offering 7.8 million shares at $15, the low end of the range of $15 to $17. vTv Therapeutics plans to list on the Nasdaq under the symbol VTVT...read more
Week ahead: 10 IPOs set to price during the week of July 27
The largest biotech ever to go public is on the calendar for this week, targeting a $2.2 billion valuation at IPO. Ten IPOs and two blank check companies plan to raise over $2...read more
Alzheimer's biotech vTv Therapeutics sets terms for $125 million IPO
vTv Therapeutics, a biotech developing treatments for Alzheimer's disease and type 2 diabetes, announced terms for its IPO on Monday. The High Point, NC-based company plans to raise $125 million by offering 7.8 million shares at a price range of $15 to $17....read more